Literature DB >> 9531484

Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3.

S Cowell1, V Knäuper, M L Stewart, M P D'Ortho, H Stanton, R M Hembry, C López-Otín, J J Reynolds, G Murphy.   

Abstract

SW1353 chondrosarcoma cells cultured in the presence of interleukin-1, concanavalin A or PMA secreted procollagenase 3 (matrix metalloproteinase-13). The enzyme was detected in the culture medium by Western blotting using a specific polyclonal antibody raised against recombinant human procollagenase 3. Oncostatin M enhanced the interleukin-1-induced production of procollagenase 3, whereas interleukin-4 decreased procollagenase 3 synthesis. The enzyme was latent except when the cells had been treated with concanavalin A, when a processed form of 48 kDa, which corresponds to the active form, was found in the culture medium and collagenolytic activity was detected by degradation of 14C-labelled type I collagen. The concanavalin A-induced activation of procollagenase 3 coincided with the processing of progelatinase A (matrix metalloproteinase-2) by the cells, as measured by gelatin zymography. In addition, progelatinase B (matrix metalloproteinase-9) was activated when gelatinase A and collagenase 3 were in their active forms. Concanavalin A treatment of SW1353 cells increased the amount of membrane-type-1 matrix metalloproteinase protein in the cell membranes, suggesting that this membrane-bound enzyme participates in an activation cascade involving collagenase 3 and the gelatinases. This cascade was effectively inhibited by tissue inhibitors of metalloproteinases-2 and -3. Tissue inhibitor of metalloproteinases-1, which is a much weaker inhibitor of membrane-type 1 matrix metalloproteinase than tissue inhibitors of metalloproteinases-2 and -3 [Will, Atkinson, Butler, Smith and Murphy (1996) J. Biol. Chem. 271, 17119-17123], was a weaker inhibitor of the activation cascade.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531484      PMCID: PMC1219375          DOI: 10.1042/bj3310453

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

Review 1.  The role of plasminogen activators in the regulation of connective tissue metalloproteinases.

Authors:  G Murphy; S Atkinson; R Ward; J Gavrilovic; J J Reynolds
Journal:  Ann N Y Acad Sci       Date:  1992-12-04       Impact factor: 5.691

2.  The interaction between retinoic acid and the transforming growth factors-beta in calf articular cartilage organ cultures.

Authors:  T I Morales; A B Roberts
Journal:  Arch Biochem Biophys       Date:  1992-02-14       Impact factor: 4.013

3.  Collagenase 3 (matrix metalloproteinase 13) gene expression by HaCaT keratinocytes is enhanced by tumor necrosis factor alpha and transforming growth factor beta.

Authors:  N Johansson; J Westermarck; S Leppä; L Häkkinen; L Koivisto; C López-Otín; J Peltonen; J Heino; V M Kähäri
Journal:  Cell Growth Differ       Date:  1997-02

4.  Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1.

Authors:  M Mohtai; R L Smith; D J Schurman; Y Tsuji; F M Torti; N I Hutchinson; W G Stetler-Stevenson; G I Goldberg
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

5.  Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9.

Authors:  Y Ogata; J J Enghild; H Nagase
Journal:  J Biol Chem       Date:  1992-02-25       Impact factor: 5.157

6.  The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A.

Authors:  F Willenbrock; T Crabbe; P M Slocombe; C W Sutton; A J Docherty; M I Cockett; M O'Shea; K Brocklehurst; I R Phillips; G Murphy
Journal:  Biochemistry       Date:  1993-04-27       Impact factor: 3.162

7.  Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes.

Authors:  R V Ward; S J Atkinson; P M Slocombe; A J Docherty; J J Reynolds; G Murphy
Journal:  Biochim Biophys Acta       Date:  1991-08-30

8.  The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1.

Authors:  R V Ward; R M Hembry; J J Reynolds; G Murphy
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

9.  Characterization of a specific antiserum for mammalian collagenase from several species: immunolocalization of collagenase in rabbit chondrocytes and uterus.

Authors:  R M Hembry; G Murphy; T E Cawston; J T Dingle; J J Reynolds
Journal:  J Cell Sci       Date:  1986-03       Impact factor: 5.285

10.  Binding of latent and high Mr active forms of stromelysin to collagen is mediated by the C-terminal domain.

Authors:  J A Allan; R M Hembry; S Angal; J J Reynolds; G Murphy
Journal:  J Cell Sci       Date:  1991-08       Impact factor: 5.285

View more
  34 in total

Review 1.  Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment.

Authors:  M D Howell; P E Gottschall
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

2.  MT1-MMP as a downstream target of BCR-ABL/ABL interactor 1 signaling: polarized distribution and involvement in BCR-ABL-stimulated leukemic cell migration.

Authors:  X Sun; Y Li; W Yu; B Wang; Y Tao; Z Dai
Journal:  Leukemia       Date:  2007-10-18       Impact factor: 11.528

3.  Matrix metalloproteinase-13 expression in the progression of colorectal adenoma to carcinoma : Matrix metalloproteinase-13 expression in the colorectal adenoma and carcinoma.

Authors:  Abd Al-Rahman Mohammad Foda; Amira K El-Hawary; Azza Abdel-Aziz
Journal:  Tumour Biol       Date:  2014-02-23

4.  Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli.

Authors:  Christopher B Forsyth; Ada Cole; Gillian Murphy; Julia L Bienias; Hee-Jeong Im; Richard F Loeser
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2005-09       Impact factor: 6.053

5.  The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases.

Authors:  Heather Stanton; Linh Ung; Amanda J Fosang
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

6.  Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production.

Authors:  Hitesh S Deshmukh; Anne McLachlan; Jeffrey J Atkinson; William D Hardie; Thomas R Korfhagen; Maggie Dietsch; Yang Liu; Peter Y P Di; Scott C Wesselkamper; Michael T Borchers; George D Leikauf
Journal:  Am J Respir Crit Care Med       Date:  2009-08-06       Impact factor: 21.405

7.  Expression of MT1-MMP during deciduous tooth resorption in odontoclasts.

Authors:  Busayarat Linsuwanont-Santiwong; Yuzo Takagi; Keiichi Ohya; Hitoyata Shimokawa
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain.

Authors:  Hidetoshi Mori; Taizo Tomari; Naohiko Koshikawa; Masahiro Kajita; Yoshifumi Itoh; Hiroshi Sato; Hideaki Tojo; Ikuo Yana; Motoharu Seiki
Journal:  EMBO J       Date:  2002-08-01       Impact factor: 11.598

Review 9.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

10.  MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma.

Authors:  Wiltrud Lederle; Bettina Hartenstein; Alice Meides; Heike Kunzelmann; Zena Werb; Peter Angel; Margareta M Mueller
Journal:  Carcinogenesis       Date:  2009-11-05       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.